



Our ref: AA1000472  
Contact officer: Andrew Mahony  
Contact phone: (03) 9290 1983

23 Marcus Clarke Street  
Canberra ACT 2601

GPO Box 3131  
Canberra ACT 2601

tel: (02) 6243 1111  
exemptions@accc.gov.au  
www.accc.gov.au

10 December 2020

Dear Madam/Sir,

**eRx Script Exchange Pty Ltd application for authorisation AA1000472—determination**

The Australian Competition and Consumer Commission (the ACCC) has issued a determination in respect of the application for authorisation lodged by eRx Script Exchange Pty Ltd (**eRx**) on 2 March 2020.

eRx sought re-authorisation to continue a revenue sharing arrangement with IP MDS Pty Ltd in order to facilitate interoperability between their two Prescription Exchange Systems.

A copy of the ACCC's determination is attached. For the reasons set out in its determination, the ACCC has decided to grant authorisation until 30 June 2025.

**Application for review**

Pursuant to section 101 of the *Competition and Consumer Act 2010*, a person dissatisfied with this determination may apply to the Australian Competition Tribunal for its review. An application for review must be made within 21 days of the date of this determination; that is, on or before 31 December 2020. If no application to review is lodged by this date, the ACCC's determination will come into force on 1 January 2021.

An application for review of the ACCC's determination should be lodged directly with the Australian Competition Tribunal. The Australian Competition Tribunal is a separate body from the ACCC and is located within the Federal Court of Australia.

For further information about the process involved in reviewing decisions in the Australian Competition Tribunal please refer to the tribunal's [website](#).

This letter has been placed on the ACCC's public register. If you wish to discuss any aspect of this matter please contact Andrew Mahony on (03) 9290 1983.

Yours sincerely,

Darrell Channing  
Director  
Competition Exemptions